Table 5.
Mean and standard deviation of MG-ADL and QMG scores in Bulbar signs at the beginning and at the end of each cycle of therapy with Efgartigimod.
| Bulbar signs in MG-ADL assessment in all patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° Cycle | 2° Cycle | 3° Cycle | p value | ||||||||
| MG-ADL | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 3.88 | 1.13 | 2.13 | 0.88 | 3.20 | 1.20 | 0.030 | 0.010 | 0.11 | 0.012 | 0.021 |
| SD | 2.00 | 1.66 | 1.23 | 1.88 | 1.58 | 1.54 | |||||
| Bulbar signs in QMG assessment in all patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° cycle | 2° cycle | 3° cycle | |||||||||
| QMG | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 2.50 | 0.50 | 1.43 | 0.86 | 2.40 | 0.60 | 0.018 | 0.10 | 0.12 | 0.041 | 0.034 |
| SD | 1.79 | 1.39 | 1.49 | 1.43 | 2.00 | 0.83 | |||||
* Repeated measures ANOVA with Post Hoc analysis using Bonferroni method.